Neoadjuvant Therapy for MIBC in the Genomic Era
Colin P.N. Dinney, MD, discusses the promise of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the genomic era.
Read MoreSelect Page
Colin P. N. Dinney, MD, is Chairman of the Department of Urology, Division of Surgery, and also co-chairs the Genitourinary Steering Committee for the Bladder Task Force at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Dinney earned his MD from the University of Winnipeg, Canada and completed his residency in urology at Dalhousie University in Halifax, before moving to Houston to begin his work with the MD Anderson Cancer Center. He has published over twenty peer-reviewed articles and currently serves as a professor in the Department of Cancer Biology at the University of Texas. He is recognized as one of Houston’s top urologists and has been awarded numerous honors, such as the 2015 Society of Urologic Oncology Medal. His other appointments include serving as Co-Chair of the Orthopedic Oncology Chair Search Committee, as well as past-director of the Bladder Organ Site Committee of the Society of Urologic Oncology Clinical Trials Consortium.
Disclosures:Posted by Colin P. N. Dinney, MD | May 2023
Colin P.N. Dinney, MD, discusses the promise of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the genomic era.
Read More